RU2707092C2 - Составы со сниженным окислением - Google Patents

Составы со сниженным окислением Download PDF

Info

Publication number
RU2707092C2
RU2707092C2 RU2015143548A RU2015143548A RU2707092C2 RU 2707092 C2 RU2707092 C2 RU 2707092C2 RU 2015143548 A RU2015143548 A RU 2015143548A RU 2015143548 A RU2015143548 A RU 2015143548A RU 2707092 C2 RU2707092 C2 RU 2707092C2
Authority
RU
Russia
Prior art keywords
antibody
composition
oxidation
antibodies
protein
Prior art date
Application number
RU2015143548A
Other languages
English (en)
Russian (ru)
Other versions
RU2015143548A (ru
Inventor
Сридхара Алаваттам
Мэри МЭЛЛЭНИ
Парбир ГРЕВАЛ
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2015143548A publication Critical patent/RU2015143548A/ru
Application granted granted Critical
Publication of RU2707092C2 publication Critical patent/RU2707092C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Lubricants (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2015143548A 2013-03-13 2014-03-13 Составы со сниженным окислением RU2707092C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780845P 2013-03-13 2013-03-13
US61/780,845 2013-03-13
US201361909813P 2013-11-27 2013-11-27
US61/909,813 2013-11-27
PCT/US2014/026841 WO2014160495A1 (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Publications (2)

Publication Number Publication Date
RU2015143548A RU2015143548A (ru) 2017-04-20
RU2707092C2 true RU2707092C2 (ru) 2019-11-22

Family

ID=51625442

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015143548A RU2707092C2 (ru) 2013-03-13 2014-03-13 Составы со сниженным окислением

Country Status (23)

Country Link
EP (1) EP2968466B1 (https=)
JP (3) JP6389236B2 (https=)
KR (1) KR102237885B1 (https=)
CN (2) CN110075293A (https=)
AU (3) AU2014243700B2 (https=)
CA (2) CA2904166C (https=)
DK (1) DK2968466T3 (https=)
ES (1) ES2688895T3 (https=)
HR (1) HRP20181504T1 (https=)
HU (1) HUE039948T2 (https=)
IL (2) IL269947B (https=)
LT (1) LT2968466T (https=)
MX (2) MX369671B (https=)
MY (2) MY174679A (https=)
NZ (1) NZ711566A (https=)
PL (1) PL2968466T3 (https=)
PT (1) PT2968466T (https=)
RS (1) RS57813B1 (https=)
RU (1) RU2707092C2 (https=)
SG (2) SG11201507043SA (https=)
SI (1) SI2968466T1 (https=)
WO (1) WO2014160495A1 (https=)
ZA (2) ZA201506876B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2858996C2 (ru) * 2021-02-19 2026-03-25 Инхибркс Байосайенсиз, Инк. Составы dr5-связывающих полипептидов

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2707550C2 (ru) * 2013-03-13 2019-11-27 Дженентек, Инк. Составы со сниженным окислением
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2018002031A1 (en) 2016-06-27 2018-01-04 Morphosys Ag Anti-cd19 antibody formulations
JP7076109B2 (ja) * 2017-10-13 2022-05-27 株式会社タムラテコ 有害物処理方法およびオゾン発生装置
KR102898177B1 (ko) 2018-08-08 2025-12-10 제넨테크, 인크. 단백질 제제를 위한 트립토판 유도체 및 l-메티오닌의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260230A1 (en) * 2000-02-29 2002-11-27 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
US20100068210A1 (en) * 2008-09-10 2010-03-18 Ji Junyan A Compositions and methods for the prevention of oxidative degradation of proteins
WO2010032220A1 (en) * 2008-09-19 2010-03-25 Pfizer Inc. Stable liquid antibody formulation
RU2010136488A (ru) * 2010-08-30 2012-03-10 Государственное образовательное учреждение высшего профессионального образования "Оренбургский государственный университет" (RU) Способ стабилизации антител в водных растворах

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6498236B1 (en) 1996-08-30 2002-12-24 Upfront Chromatography A/S Isolation of immunoglobulins
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
CA2368734C (en) 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2005524601A (ja) * 2000-09-15 2005-08-18 ザ スクリップス リサーチ インスティテュート 抗体による過酸化水素およびスーパーオキシド生成に関する方法および組成物
US6933123B2 (en) * 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
JP2005519580A (ja) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
RS51829B (sr) 2001-08-23 2012-02-29 Genmab A/S. Ljudska antitela specifična za interleukin 15 (il-15)
ATE414537T1 (de) * 2001-08-29 2008-12-15 Chugai Pharmaceutical Co Ltd Antikörper enthaltende stabilisierte zubereitungen
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
EP1590434A4 (en) 2003-01-17 2006-11-29 Univ New York State Res Found ASSOCIATED ANTIGEN, ANTIBODIES, AND DIAGNOSIS AND TREATMENT METHODS WITH CONCENTRATED CANNULA CANCER
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1633785B1 (en) 2003-05-21 2012-11-28 Medarex, Inc. Human monoclonal antibodies against bacillusanthracis protective antigen
US7741071B2 (en) * 2003-12-18 2010-06-22 The Scripps Research Institute Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
WO2007095288A2 (en) * 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
CN101616685B (zh) * 2006-03-06 2013-07-24 阿穆尼克斯运营公司 非结构化重组聚合物和其应用
JP2007319124A (ja) * 2006-06-02 2007-12-13 Nippon Tablet Kk 健康食品
ES2660173T3 (es) * 2007-01-16 2018-03-21 Ipintl, Llc Nueva composición para el tratamiento del síndrome metabólico
KR101715631B1 (ko) * 2008-04-01 2017-03-13 안티포딘 파마슈티칼스, 인코포레이티드 피부 관리를 위한 조성물 및 방법
AU2009283157B2 (en) * 2008-08-21 2015-02-26 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
SG186783A1 (en) * 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
WO2012170883A1 (en) * 2011-06-09 2012-12-13 Discovery Pharma Consulting, Llc Antihistamines combined with dietary supplements for improved health
EP2726495B1 (en) * 2011-06-28 2019-03-06 Leukocare Ag Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260230A1 (en) * 2000-02-29 2002-11-27 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
US20100068210A1 (en) * 2008-09-10 2010-03-18 Ji Junyan A Compositions and methods for the prevention of oxidative degradation of proteins
WO2010032220A1 (en) * 2008-09-19 2010-03-25 Pfizer Inc. Stable liquid antibody formulation
RU2010136488A (ru) * 2010-08-30 2012-03-10 Государственное образовательное учреждение высшего профессионального образования "Оренбургский государственный университет" (RU) Способ стабилизации антител в водных растворах

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CADENAS E et al.: "Antioxidant activity of *
CADENAS E et al.: "Antioxidant activity of 5-hydroxytryptophan, 5-hydroxyindole, and DOPA against microsomal lipid peroxidation and its dependence on vitamin E", 1989, FREE RADICAL RESEARCH COMMUNICATIONS, VOL. 6, NR. 1, стр. 11-17. *
CHRISTEN, S et al. Antioxidant Activities of Some Tryptophan Metabolites: Possible Implication for Inflammatory Diseases. Proceeding of the National Academy of Sciences.-1990.- Vol. 87, стр. 2506-2510. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2858996C2 (ru) * 2021-02-19 2026-03-25 Инхибркс Байосайенсиз, Инк. Составы dr5-связывающих полипептидов

Also Published As

Publication number Publication date
RU2015143548A (ru) 2017-04-20
JP6389236B2 (ja) 2018-09-12
LT2968466T (lt) 2018-10-10
MY174679A (en) 2020-05-06
CA2904166A1 (en) 2014-10-02
AU2014243700A1 (en) 2015-10-08
PT2968466T (pt) 2018-10-22
JP2018150317A (ja) 2018-09-27
CN104968362B (zh) 2018-12-14
CN110075293A (zh) 2019-08-02
AU2021201366A1 (en) 2021-03-18
MX2015011432A (es) 2016-04-27
DK2968466T3 (en) 2018-10-22
IL240933B (en) 2019-10-31
SG10201705525VA (en) 2017-08-30
MX2019013560A (es) 2020-01-20
IL269947A (https=) 2019-12-31
EP2968466B1 (en) 2018-07-25
AU2019202464A1 (en) 2019-05-02
MY199135A (en) 2023-10-17
KR20150130397A (ko) 2015-11-23
ZA201906057B (en) 2022-04-28
AU2019202464B2 (en) 2020-12-10
SI2968466T1 (sl) 2018-10-30
BR112015022484A2 (pt) 2017-07-18
IL240933A0 (en) 2015-11-30
PL2968466T3 (pl) 2018-11-30
HK1211219A1 (en) 2016-05-20
RS57813B1 (sr) 2018-12-31
IL269947B (en) 2022-08-01
EP2968466A4 (en) 2016-10-26
SG11201507043SA (en) 2015-10-29
NZ751543A (en) 2020-09-25
CA2904166C (en) 2021-05-18
ZA201506876B (en) 2019-12-18
HUE039948T2 (hu) 2019-02-28
CN104968362A (zh) 2015-10-07
JP2016520521A (ja) 2016-07-14
KR102237885B1 (ko) 2021-04-07
CA3113172A1 (en) 2014-10-02
NZ711566A (en) 2020-06-26
ES2688895T3 (es) 2018-11-07
EP2968466A1 (en) 2016-01-20
JP2020164531A (ja) 2020-10-08
AU2014243700B2 (en) 2019-01-24
WO2014160495A1 (en) 2014-10-02
MX369671B (es) 2019-11-15
HRP20181504T1 (hr) 2018-11-02

Similar Documents

Publication Publication Date Title
US20260060959A1 (en) Formulations with reduced oxidation
AU2019202464B2 (en) Formulations with reduced oxidation
US10653779B2 (en) Formulations with reduced oxidation
RU2707550C2 (ru) Составы со сниженным окислением
JP2016520521A5 (https=)
NZ751543B2 (en) Formulations with reduced oxidation
BR112015022484B1 (pt) Formulação líquida, seu método de produção, e método para impedir a oxidação de uma proteína na dita formulação líquida
BR112015022475B1 (pt) Formulação líquida compreendendo um anticorpo em combinação com um composto que impede a oxidação de um anticorpo
HK1211219B (zh) 氧化降低的配制剂